R3Mab

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (10)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR3 S249C1
R3Mab	Bladder Carcinoma

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

FGFR3 G370C1
R3Mab	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID10353 Ba/F3 cells transfected with wild type FGFR3 or common bladder carcinoma variant FGFR3 G372C both resulted in IL-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment wit… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic

FGFR3 K650E2
R3Mab	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID10355 Ba/F3 cells transfected with wildtype FGFR3 resulted in IL-3 independence with FGF1 dependence for growth, whereas cells transfected with common bladder carcinoma variant FGFR3 K652E resulted in IL-3 … (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	4	submitted	EID10365 In culture, monoclonal antibody R3Mab treatment inhibited the growth of multiple myeloma cell line UTMC-2 which has wild type FGFR3 but did not affect proliferation of multiple myeloma cell line KMS11… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic

FGFR3 Overexpression3
R3Mab	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10352 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pr… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	4	rejected	EID10363 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pro… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	4	submitted	EID10364 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of pro… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic

FGFR3 R248C1
R3Mab	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID8321 In this preclinical study, R3Mab (a monoclonal antibody specific to FGFR3) inhibited ligand-independent proliferation in Ba/F3 cells expressing common bladder carcinoma variant: FGFR3 R248C. Authors n… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic

FGFR3 Y373C2
R3Mab	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID10354 Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in IL-3 independence with FGF1 dependence for growth. Cell transfected FGFR3 with mutation Y375C also resulted in IL-3 independence and FGF1… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Sensitivity Response	4	submitted	EID10366 In culture, monoclonal antibody R3Mab treatment inhibited the growth of multiple myeloma cell line UTMC-2 which has wild type FGFR3 but did not affect proliferation of multiple myeloma cell line KMS11… (full text at CIViC) PMID 19381019 · Qing et al., 2009 · Open in CIViC	civic